Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991641 | 0.92 | MEN1 (0.36) | PDK2PPARAKDM4EPOLBSSTR4 | |
| SCHEMBL12925102 | 0.91 | TRPM8 (0.36) | PDK2PPARAKDM4EPOLBSSTR4 | |
| SCHEMBL12925100 | 0.87 | PDK2 (0.35) | PDK2PPARAKDM4EPOLBSSTR4 | |
| SCHEMBL991770 | 0.84 | PDK2 (0.48) | PDK2PPARAKDM4EPOLBPPARG | |
| SCHEMBL2480421 | 0.84 | BCHE (0.41) | BCHEACHE | |
| SCHEMBL6181833 | 0.82 | MEN1 (0.36) | PDK2PPARAKDM4EPOLBSSTR4 | |
| SCHEMBL4890440 | 0.82 | ADRB3 (0.40) | PDK2KDM4EPOLB | |
| SCHEMBL12177889 | 0.81 | PDK2 (0.43) | BCHEACHEPDK2PPARAKDM4E | |
| SCHEMBL991360 | 0.78 | PDK2 (0.43) | PDK2PPARAKDM4EPOLB | |
| SCHEMBL2481800 | 0.78 | NPC1 (0.44) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129763-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129763-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, SI, DNPEP | BCHE 1023/4885ACHE 3458/4885PDK2 2742/4885 |
| US-20110015119-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | SI, FUT6, B3GAT3 | BCHE 732/4885ACHE 2849/4885PDK2 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.